Gene therapy available for all patients
Socially responsible pricing
We are here for the patient
LentiCure is publicly owned: full subsidiary of Erasmus MC Holding
Open and transparent
Society pays, so it has the right to information
We are committed to a future in which all rare genetic diseases can be treated with gene therapy at socially acceptable costs.
We are committed to a future in which all rare genetic diseases can be treated with gene therapy at socially acceptable costs.
Stay up to date
Living with Pompe disease: what do patients report?
Tuesday, July 14, 2026
What does Pompe disease really mean for patients' daily lives? The 2024 Pompe Survey Report offers a unique perspective.
Podcast: Research is the key – Let’s Talk Business
Tuesday, July 14, 2026
The Prinses Beatrix Spierfonds funds, guides, and stimulates scientific research into muscle diseases, because it knows that scientific research is the only key to making all muscle diseases treatable in the future. Listen to the New Business Radio podcast Let’s Talk Business #634.
Donate to the Spierfonds and make a difference
Tuesday, July 14, 2026
Every day, people with a muscle disease need our help. With your donation, you help make groundbreaking research possible, improve treatments, and give hope to thousands of people in the Netherlands. Discover why your contribution can have such an impact.